Herantis Pharma granted a U.S. patent on therapeutic use of MANF
Herantis Pharma granted a U.S. patent on therapeutic use of MANF Herantis Pharma PlcCompany release 23 May 2017 at 9:00 am The United States Patent and Trademark Office ("USPTO") has issued to Herantis Pharma Plc ("Herantis") a patent titled "Neurotrophic factor MANF and uses thereof". The patent number 9,592,270 is for the use of MANF, or mesencephalic astrocyte-derived neurotrophic factor, for the treatment of neurological diseases including Parkinson's disease, epilepsy, and ischemic brain injury. "MANF is the only known neurotrophic and neuroprotective factor similar to our